| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT03121963 Details | 2021-06-22 Interventional | 4 | 0 | Acetaminophen Acetaminophen, … Celecoxib Gabapentin Hydrocodone Oxycodone Pain Management | This protocol was difficult to enroll into, and changes to personnel have made it difficult to
main this study. Data collection was not completed and therefore, no data analysis was
performed. The PI has made the decision to close this study. - | |||
| NCT02323230 Details | 2021-06-22 Interventional | 2 | 4 | Cyclophosphamid… Lymphoma Lymphoma, B-Cel… Lymphoma, Large… Diffuse Large B… | new study - | |||
| NCT02128230 Details | 2021-06-22 Interventional | 2 | 20 | BB 1101 Cisplatin Cyclophosphamid… Dexamethasone Dexamethasone a… Doxorubicin Etoposide Etoposide phosp… Lenalidomide Lenograstim Liposomal doxor… Melphalan Thalidomide Multiple Myelom… Neoplasms, Plas… | Low enrollment and Futility as determined by Amgen's Carfilzomib NASCR program. The study was terminated early due to futility as determined by Amgen's Carfilzomib NASCR program in addition to low enrollment. | |||
| NCT01760993 2012-003920-18 Details | 2021-06-22 Interventional | 3 | 2 | Lisdexamfetamin… Schizophrenia | Study was discontinued due to non-safety related business prioritization decisions. No subjects
were randomized. Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized | |||
| NCT01760889 2012-003919-57 Details | 2021-06-22 Interventional | 3 | 1 | Lisdexamfetamin… Schizophrenia | Study was discontinued due to non-safety related business prioritization decisions. No subjects
were randomized Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized | |||
| NCT01738698 2012-003918-14 Details | 2021-06-22 Interventional | 3 | 4 | Lisdexamfetamin… Schizophrenia | Study was discontinued due to non-safety related business prioritization decisions. No subjects
were randomized. Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized | |||
| NCT04530617 Details | 2021-06-21 Interventional | 2 | [28 Refs] | 246 | Camostat COVID-19 Covid19 Diabetes Hypertension Obesity | Results from the interim analysis - | ||
| NCT04613102 Details | 2021-06-18 Interventional | 2/3 | 0 | Cannabidiol Epidermolysis B… Itch Pain | The study protocol should to be updated (major updates), following the second Health Canada
review /requests. The study has been withdrawn form the REB review and will not be performed at
SickKids. - | |||
| NCT04234516 Details | 2021-06-18 Interventional | 4 | 0 | Buprenorphine Buprenorphine, … Morphine Naloxone Opioid-Related … Substance-Relat… Suicidal Ideati… Opioid-use Diso… | PI leaving the institute - | |||
| NCT04126343 2019-002797-31 Details | 2021-06-18 Interventional | 1 | 54 | Moxifloxacin Padsevonil Healthy Study P… | Based on available data, UCB has decided to stop development of padsevonil as adjunctive
treatment of focal-onset seizures - | |||
| NCT04039919 2019-000703-32 Details | 2021-06-18 Interventional | 1 | 40 | Padsevonil Healthy Partici… | Based on available data, UCB has decided to stop development of padsevonil as adjunctive
treatment of focal-onset seizures The study was terminated because the decision was made to terminate the PSL development program in focal-onset seizures on 22 May 2020. | |||
| NCT03809650 Details | 2021-06-18 Interventional | 3 | 9 | Macitentan Hypertension Hypertension, P… Chronic Thrombo… | Due to a change in the development strategy - | |||
| NCT03547778 Details | 2021-06-18 Interventional | 4 | 0 | Misoprostol Office Hysteros… | Unable to get patients interested in the study - | |||
| NCT03528564 Details | 2021-06-18 Interventional | 2 | 4 | Epoetin Alfa Ferric Oxide, S… Anemia Anemia, Iron-De… Chronic Disease Iron Deficienci… Joint Diseases Anemia of Chron… Anemia, Iron De… Hip Arthropathy Knee Arthropath… | The primary reasoning is that we were unable to demonstrate feasibility, prior to and because
of the impact of COVID on our research programs. - | |||
| NCT01823835 2014-004852-77 Details | 2021-06-18 Interventional | 1/2 | 152 | Palbociclib Breast Neoplasm… Breast Cancer | The Sponsor decided to halt the development of GDC-0810, but not due to any safety concerns. - | |||
| NCT01562041 Details | 2021-06-18 Interventional | 2 | 14 | Ranolazine Cardiovascular … Vascular Diseas… Atherosclerotic… | - - | |||
| NCT04611776 Details | 2021-06-16 Interventional | 2 | 0 | Atezolizumab Carboplatin Gemcitabine Paclitaxel Pemetrexed Carcinoma, Non-… Carcinoma, Non-… | The positive results from IMpower010 demonstrated benefit by adding atezolizumab as adjuvant
therapy in early stage NSCLC. These results raised ethical concerns of enrolling pts to best
supportive care over checkpoint inhibition in this setting. - | |||
| NCT04579133 Details | 2021-06-16 Interventional | 2 | 140 | Durvalumab Olaparib Carcinoma Carcinoma, Tran… Urinary Bladder… Bladder Cancer Urothelial Carc… | Not approved - | |||
| NCT03768726 Details | 2021-06-16 Interventional | 3 | 23 | Ziprasidone Bipolar Disorde… | Pfizer has decided to perform the pre-specified final analysis at the current enrollment using
a re-estimation of the sample size. Prioritization of outcome measures per study team's discretion. | |||
| NCT02075047 Details | 2021-06-16 Interventional | 3 | 171 | Ziprasidone Bipolar Disorde… | Based on recent input from FDA, the pre-specified final analysis will be performed at the
current enrollment using a re-estimation of the sample size. - |